Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | terminated | Phase 2 | 1 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT04899349 | Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant(EPIK-B4) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 9, 2024 | clinicaltrials |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT02681523 | ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.(ALERT) | terminated | Phase 2 | 8 | Imperial College LondonOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03043794 | Study of Stereotactic Radiotherapy for Breast Cancer | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05966584 | A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer | terminated | Phase 2 | 1 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | terminated | Phase 2 | 3 | Xiang ZhangOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | terminated | Phase 1 / Phase 2 | 9 | ImmunityBio, Inc.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin | terminated | Phase 2 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04862143 | Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant(TELEPIK) | terminated | Phase 2 | 2 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05163223 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer(Cornerstone001) | terminated | Phase 2 | 10 | Aston Sci. Inc.INDUSTRY | 2 | Jun 17, 2024 | clinicaltrials |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 12, 2024 | clinicaltrials |
| NCT02540330 | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant(007) | terminated | Phase 2 | 3 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | terminated | Phase 2 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT01616758 | Phase II Study of GTx024 in Women With Metastatic Breast Cancer | terminated | Phase 2 | 22 | GTxINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04927481 | A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer | terminated | Phase 2 | 28 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer(TENACITY) | terminated | Phase 2 | 18 | Ayala Pharmaceuticals, Inc,INDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | terminated | Phase 1 / Phase 2 | 26 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04714619 | CB-103 Plus NSAI In Luminal Advanced Breast Cancer(CAILA) | terminated | Phase 2 | 2 | MedSIROTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT00679029 | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer | terminated | Phase 2 | 15 | University of NebraskaOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT06161792 | Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer(VMS) | terminated | Phase 2 | 10 | Yung Shin Pharm. Ind. Co., Ltd.INDUSTRY | 1 | Dec 8, 2023 | clinicaltrials |
| NCT02642094 | Aging Mammary Stem Cells and Breast Cancer Prevention | terminated | Phase 2 | 58 | LuZhe SunOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer(TARA) | terminated | Phase 2 | 1 | Mylin A. Torres, MDOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT01990352 | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | terminated | Phase 2 | 24 | University of ArizonaOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer | terminated | Phase 2 | 8 | Montefiore Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04149522 | Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer | terminated | Phase 2 | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03916068 | Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy | terminated | Phase 2 | 1 | Legacy Health SystemOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT01276704 | Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer | terminated | Phase 2 | 180 | Carol Fabian, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00934895 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca | terminated | Phase 1 / Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT00665457 | Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery | terminated | Phase 2 | 3 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT02585388 | Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.(CHEOPS) | terminated | Phase 2 | 120 | ARCAGY/ GINECO GROUPOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT04720664 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer(OASIS) | terminated | Phase 2 | 11 | Georgetown UniversityOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT03329378 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | terminated | Phase 2 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT00765765 | Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Nov 20, 2024source: clinicaltrials